丰原药业(000153) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was CNY 1,743,408,446.49, representing a 10.50% increase compared to CNY 1,577,762,403.83 in the same period last year[26]. - The net profit attributable to shareholders of the listed company was CNY 63,582,479.55, up 10.10% from CNY 57,751,474.43 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 44,319,138.72, reflecting a 15.34% increase from CNY 38,423,723.93 in the previous year[26]. - The total profit before tax was CNY 90,139,500, reflecting a 16.99% increase year-on-year[33]. - The operating profit was CNY 88,356,300, marking a 15.89% increase from the previous year[33]. - The company reported a total profit of CNY 90,139,512.10 for the first half of 2021, compared to CNY 77,047,786.78 in the same period last year, marking a 17.0% increase[123]. Cash Flow and Assets - The net cash flow from operating activities was CNY 76,183,345.95, a significant increase of 200.10% compared to CNY 25,385,836.31 in the same period last year[26]. - The company's cash and cash equivalents increased by 152.54%, reaching CNY 26,575,913.28[38]. - Cash and cash equivalents at the end of the period increased to ¥279,350,705.24 from ¥204,739,118.44, marking a growth of 36.3%[130]. - The total assets at the end of the reporting period were CNY 3,799,524,741.03, which is a 4.49% increase from CNY 3,636,207,572.40 at the end of the previous year[26]. - The total current assets amounted to ¥1,792,176,172.35, compared to ¥1,738,288,251.02 at the end of 2020, reflecting an increase of approximately 3.1%[114]. Shareholder Information - The total number of shares is 312,141,230, with 99.95% being unrestricted shares[99]. - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 11.48% of shares, totaling 35,842,137 shares[102]. - The company did not distribute cash dividends or issue bonus shares[9]. - The company did not experience any major litigation or arbitration matters during the reporting period[80]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 37,314,532.78, which is an 83.66% increase compared to the previous year[38]. - The company operates in the pharmaceutical manufacturing industry, focusing on the production and sales of various drug forms including large-volume injections and small-volume injections[147]. Subsidiaries and Investments - The company established a new wholly-owned subsidiary, Anhui Fengyuan Weikang Raw Material Pharmaceutical Co., Ltd., through its subsidiary, which may impact overall production and performance positively[58]. - The consolidated financial statements include 17 subsidiaries, all of which are wholly owned or controlled by the company[149]. Financial Position and Equity - The total equity at the end of the reporting period is CNY 895,613,733.62, down from CNY 924,105,564.22 at the beginning of the year, reflecting a decrease of approximately 3.08%[140]. - The total liabilities increased to CNY 2,290,815,494.18 from CNY 2,188,230,845.23, reflecting a growth of about 4.7%[116]. - The company's retained earnings rose to CNY 582,473,518.00 from CNY 518,891,038.45, an increase of approximately 12.2%[116]. Compliance and Governance - Environmental compliance measures are in place, with all pollution control facilities operational and meeting national standards[70]. - The company confirmed that there were no major related party transactions during the reporting period[87]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[152]. Financial Reporting and Standards - The financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the company's financial position as of June 30, 2021[154]. - The semi-annual financial report was not audited[78]. Risk Management - The company faced risks from the implementation of drug policies such as consistency evaluation and centralized procurement, which could alter market competition dynamics[60]. - The company is actively monitoring investment risks associated with venture capital funds due to potential long investment recovery periods and market fluctuations[60].